Drug details

Toujeo U 300 (insulin glargine injection for subcutaneous use)

type of Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins, Antidiabetics, Biguanides

Toujeo U-300 (insulin glargine) is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus.

This drug may have the following side effects:

• itching,
• rash,
• allergic reactions,
• weight gain.
• injection site reactions,
• low blood sugar (hypoglycemia),
• uneven fat distribution (lipodystrophy),
• fluid retention (edema), and

The following drugs are related to Toujeo U 300, either as a replacement or used together:

• Actos (pioglitazone hydrochloride)
• Baqsimi (glucagon nasal powder)
• Lantidra (donislecel-jujn allogeneic pancreatic islet cellular)
• Trulicity (dulaglutide injection, for subcutaneous use)
• Jardiance (empagliflozin tablets)
• Tresiba (insulin degludec injection)
• Toujeo (insulin glargine injection for subcutaneous use)
• Novolin N (insulin isophane)
• Ozempic (semaglutide injection)
• Tzield (teplizumab-mzwv injection, for intravenous use)